The duo from the Critical Path Institute detailed the thought process behind evaluating the importance of specific biomarkers and their relation to disability progression in Alzheimer disease.
Klaus Romero, MD, MS, FCP
Advertisement
Articles by Klaus Romero, MD, MS, FCP
The duo from the Critical Path Institute discussed how CPAD is revolutionizing data collection within the Alzheimer disease community and the advantages it brings to clinicians.
Advertisement
Latest Updated Articles
Advertisement
Advertisement
Trending on NeurologyLive - Clinical Neurology News and Neurology Expert Insights
1
Understanding Ocrelizumab’s Impact on Advanced Progressive MS: Insights From Dr. Gavin Giovannoni
2
How Multiple Sclerosis Affects Men
3
Trofinetide Leads to Real-World Improvements in Rett Syndrome Symptoms, LOTUS Study Finds
4
Key Highlights from the 2025 American Neurological Association Annual Meeting
5
